August 2024 – Page 7

Novartis and Versant Ventures Launch Borealis Biosciences to Develop RNA Medicines for Kidney Diseases

8 months ago talkbio0Tagged Biosciences, Biotechnology, Borealis, Kidney, Kidney Diseases, Novartis, RNA, RNA medicines, startup, Ventures, Versant, xRNA

Borealis Biosciences, Novartis, Versant Ventures, RNA medicines, kidney diseases, xRNA technology, biotechnology, startup, kidney research, RNA therapeutics.

Rafael Holdings and Cyclo Therapeutics Merge to Accelerate Development of Niemann-Pick Disease Type C1 Treatment

8 months ago talkbio0Tagged Clinical Trials, Cyclo Therapeutics, Drug Development, Holdings, Niemann-Pick Disease, Type C1, Rafael, Trappsol Cyclo

Rafael Holdings, Cyclo Therapeutics, merger, Niemann-Pick Disease Type C1, Trappsol Cyclo, clinical trial, pharmaceutical development

WuXi AppTec Unfazed by BIOSECURE Act Threat, Secures New US Deals

8 months ago talkbio0Tagged AppTec, BIOSECURE, biotech, deals, Industry, pharmaceutical manufacturing, U.S., WuXi

WuXi AppTec, BIOSECURE Act, US Deals, Pharmaceutical Manufacturing, Biotech Industry

UK Approves Leqembi for Alzheimer’s, but NICE Deems It Too Costly for NHS Use

8 months ago talkbio0Tagged Alzheimer 's disease, Approved, Cost Effectiveness, Leqembi, Nance-Horan syndrome, NICE, Nitroglycerin/Sodium Citrate/Ethanol Solution, UK

Leqembi, Alzheimer’s disease, NICE, NHS, cost-effectiveness, UK approval

FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection

8 months ago talkbio0Tagged Approved, authorization, COVID19 (disease), Emergency Situation, Guidelines, JN.1, KP.2, Lineage, Moderna, Pfizer, Pfizer/, RNA, Messenger, United States Food and Drug Administration, Vaccination, Vaccines, Variant

COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.